Navigation Links
WellPoint Statement on CMS Action
Date:1/12/2009

hich generally are not historical in nature. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: those discussed and identified in our public filings with the U.S. Securities and Exchange Commission, or SEC; increased government regulation of health benefits, managed care and PBM operations; trends in health care costs and utilization rates; our ability to secure sufficient premium rate increases; our ability to contract with providers consistent with past practice; competitor pricing below market trends of increasing costs; reduced enrollment, as well as a negative change in our health care product mix; risks and uncertainties regarding the Medicare Part C and Medicare Part D Prescription Drug benefits programs, including potential uncollectability of receivables resulting from processing and/or verifying enrollment (including facilitated enrollment), inadequacy of underwriting assumptions, inability to receive and process correct information, uncollectability of premium from members, increased medical or pharmaceutical costs, and the underlying seasonality of the business; a downgrade in our financial strength ratings; litigation and investigations targeted at health benefits companies and our ability to resolve litigation and investigations within estimates; our ability to meet expectations regarding repurchases of shares of our common stock; funding risks with respect to revenue received from participation in Medic
'/>"/>
SOURCE WellPoint, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. WellPoint Announces Appearances at Upcoming Conferences
2. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
3. WellPoint Announces Realignment of Core Businesses; Names New Executives
4. Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
5. WellPoint NextRx Receives National Leadership Award for Innovative Web Tool
6. WellPoint Reports Third Quarter 2007 Results
7. WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors
8. WellPoint Provides Support and Resources to Most Vulnerable California Residents
9. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
10. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
11. WellPoint Announces Appointment of John Langenus as President of Anthem National Accounts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Teens prescribed ... to abuse those drugs than other teens, a ... need to conduct substance abuse assessments on teenagers ... said. "Prescribers and parents don,t realize the ... professor at the University of Michigan School of ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/26/2014)... Randy Dotinga HealthDay Reporter ... as Prilosec and Nexium may disrupt the makeup of bacteria ... and other problems, a small new study suggests. ... likely users will become ill, and study authors aren,t recommending ... However, these antacids "should be used at the lowest dose ...
(Date:11/24/2014)... Recently, Fecbek.com ( http://www.fecbek.com ), a leading ... and introduced the history of the Black Friday to its ... after Thanksgiving? It is the Black Friday! It is a ... 11th in China. However, not everyone knows the history of ... about this special day. , The fourth Friday in November ...
Breaking Medicine News(10 mins):Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... North Carolina (UNC) at Chapel Hill have revealed that inhaling ... by cystic fibrosis (CF). Hypertonic saline// is a water-based ... ,The researchers arrived at this conclusion after testing 24 patients ... inhaling the salt solution improved the health of the lungs ...
... Pharmaceutical companies have been called upon to stop marketing ... Organization (WHO), as the parasite which causes malaria may ... Kochi, director of the WHO's malaria department, said that ... effective anti-malarials, on its own would result in the ...
... experts have warned that the new wristwatch invented by South ... can turnout to be a health hazard. They have warned ... HIV/AIDS.// There are some who have also expressed doubts if ... ,'In my mind it's a potential public health ...
... 1.107 million fowl have been killed in Turkey with the ... in the country. This has been revealed by the Turkish ... detected in as many as 13 provinces in the country, ... the bird flu has been detected are Van, Aydin, Bursa, ...
... by having their ovaries and uterus removed, if they have ... is because these women face higher chances of contracting ovarian ... as high as 40% to 60%, while it is between ... ,Women who do not have the Lynch syndrome ...
... of African Subcommittee, House Committee on International Relations has ... AIDS testing and counseling as done in Uganda. //Uganda ... effective in early diagnosis of HIV and also helps ... person due to ignorance about the disease. ...
Cached Medicine News:
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
(Date:11/26/2014)... 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... appointment of Ms. Rebecca Yingnan Zhang as ... Ms.Zhang has over 20 years of experience in ... Prior to Ms. Zhang,s appointment as the Company,s Chief ...
(Date:11/24/2014)... SEATTLE , Nov. 24, 2014 ... granted Breakthrough Therapy Designation to the company,s JCAR015 ... for the treatment of relapsed or refractory B-cell ... collaboration partner, Memorial Sloan Kettering Cancer Center, where ... "The FDA,s action is important news ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... Cardiac Science Corporation , a global leader in automated ... monitoring devices that connect to electronic medical record ... it has completed certification with Allscripts Professional ... connectivity solution for its resting ECG, stress, and Holter ...
... and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual ... a forum hosted by the National Organization for Rare Disorders ... Hamburg could share with the patient advocates her vision for ... concerns. "I come today to ask for your ...
Cached Medicine Technology:Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5NORD Hosts Forum for FDA Commissioner and Patient Leaders 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: